Skip to main content
NewslettersWatchlist

Vaccinex Inc(VCNX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.26
Day High5.70
Open:5.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
MarketBeat
MarketBeat Week in Review – 2/6 - 2/10
MarketBeat
Should Investors Buy or Sell the Vaccinex Patent News?
Globe Newswire
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation
Globe Newswire
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
Globe Newswire
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
Globe Newswire
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
Globe Newswire
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or
Globe Newswire
Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
Globe Newswire
Vaccinex Announces $6.6 Million Private Placement
Globe Newswire
Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Globe Newswire
Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021
Globe NewsWire
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
Globe NewsWire
Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting
Globe NewsWire
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease
Globe NewsWire
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Globe NewsWire
Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference
Globe NewsWire
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
Globe NewsWire
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
Globe NewsWire
Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference
Globe NewsWire
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
Globe NewsWire
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
Globe NewsWire
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Globe NewsWire
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Globe NewsWire
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
Globe NewsWire
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
Globe NewsWire
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
Globe NewsWire
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Globe NewsWire
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
Globe NewsWire
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Globe NewsWire
Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

Profile

Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.